CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (NASDAQ: HLCS) announced today that it has priced a registered direct offering of 6.4 million units, at a price of $1.00 per unit, for gross proceeds of $6.4 million before deducting underwriting discounts and commissions and estimated offering expenses. Each unit consists of one share of the company’s common stock and a warrant to buy 0.65 of a share of the company’s common stock. The warrants will be exercisable for a period of five years beginning six months after issuance, at an exercise price of $1.4385 per share. The closing of the offering is expected to take place on or about December 21, 2009, subject to the satisfaction of customary closing conditions. Thomas Weisel Partners LLC is acting as the sole book-running manager for the offering.
